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Abstract .  In three infants with neonatal lacticacidaemia, a 
deficiency in the E1 (pyruvate dehydrogenase) component of 
the pyruvate dehydrogenase complex was demonstrated in 
skin fibroblast cultures. Residual activites of the pyruvate 
dehydrogenase complex in the activated state were 1.6%, 
3.9% and 18.8% of control values, respectively. Immuno- 
precipitation of extracts of cultures skin fibroblasts grown on 
35S-methionine with anti-pyruvate dehydrogenase complex 
antibody revealed an abnormality in the Elc~-component of 
these three patients when visualised after sodium dodecyl sul- 
phate/polyacrylamide gel electrophoresis. This component ap- 
peared to have a slightly lower molecular weight than did this 
protein from control cell strains. Cell strains from other pa- 
tients with a deficiency of the pyruvate dehydrogenase com- 
plex did not exhibit this defect. Three patients also showed 
dysmorphism and developmental abnormalities of the central 
nervous system. 
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ciency - Protein polymorphism - Developmental abnor- 
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Introduct ion 
The pyruvate dehydrogenase component (El) carries out the 
first step, namely the oxidative decarboxylation of pyruvate in 
the reaction catalysed by the pyruvate dehydrogenase com- 
plex (PDHC) (Fig. l). Reports of pyruvate dehydrogenase 
(El) deficiency have described children either with ataxic 
episodes [3-5, 16] or with delayed motor and neurological 
development [8, 9, 16, 17, 18]. Other types of presentation 
resembled Leigh's encephalomyelopathy [2,7, 20] or were 
characterised by overwhelming lacticacidemia in the neonatal 
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period [9, 16, 19]. We have described 18 patients with pyru- 
vate dehydrogenase (El) deficiency [14]. One major finding 
was facial dysmorphism or microcephaly in ten of them. Here 
we describe three cases of severe pyruvate dehydrogenase de- 
ficiency with evidence of protein polymorphism in the Ela 
component. 
Materials  and methods  
Cultures of skin fibroblasts. Skin fibroblast cultures from the 
patients and age-matched controls were grown in c~-minimal 
essential medium (c~-MEM) supplemented with 10% fetal calf 
serum, ct-MEM contains 0.5 mM pyruvate as one of its growth 
consitituents. 
Measurement of enzyme activities in cultures skin fibroblasts. 
Pyruvate dehydrogenase complex activity was measured in the 
native (unstimulated) and dichloroacetate activated state by 
the method of Sheu et al. [17] modified as suggested by Hy- 
land and Leonard [10]. Pyruvate dehydrogenase (El) was 
measured as described in [3]. Dihydrolipoyl transacetylase 
was measured by the method of Butterworth et al. [6] and 
dihydrolipoyl dehydrogenase by the method of Reed and 
Wilms [13]. Pyruvate carboxylase was measured by the meth- 
od of Ballard and Hanson [1] and whole cell pyruvate oxida- 
tion as described [16]. 
Preparation of antisera. Rabbit antiserum against the purified 
pyruvate dehydrogenase complex isolated from pig heart [11] 
was prepared by an intramuscular injection followed by sub- 
cutaneous injections at weekly intervals. Pre-immune sera 
were collected and used as normal rabbit sera. Anti-pyruvate 
dehydrogenase complex antiserum was shown to inhibit pyru- 
vate dehydrogenase complex activity in solution. It was also 
shown to immunoprecipitate the antigens Elc~, E113 and the E2 
transacetylase when added to the pyruvate dehydrogenase 
complex. 
35 Immunoprecipitation of S-methionine labelled proteins. Cul- 
tured skin fibroblasts were grown to early confluence in 75 
cm 2 tissue culture flasks, one per cell strain per experiment. 
One day prior to radioactive labelling, the medium was re- 
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moved from the flasks and replaced by 10 ml c~-MEM medium 
containing 10 gM methionine. The following day the medium 
was replaced by 5 ml of the same medium supplemented with 
200 gCi/ml of 3SS-methionine (800-1,200 Ci/mmol, Amer- 
sham, Arlington Heights, Ill.). The cells were incubated over- 
night and the radioactive medium was removed. Cells were 
extracted as described by Robinson et al. [15], first with Tri- 
ton X-100 and then with carbon tetrachloride. The resulting 
solution was subjected to an immunoprecipitation sequence 
with normal rabbit serum before immunoprecipitation with 
10 pl pyruvate dehydrogenase antibody in 1 ml, 10 mM Tris- 
HC1 pH 7.4, 5 mM phenylmethyl sulphonylfluoride, l m M  
EDTA, 0,1% Triton X-100 and 1 gg/ml methionine. Immuno- 
precipitates were pelleted by the addition of IGsorb (The En- 
zyme Centre, Waltham, Mass.). The resulting pellets were 
taken up into a 1% sodium dodecyl sulphate solution for elec- 
trophoresis on 10% polyacrylamide slab gels. 
3sS-labelled protein bands were visualised by fluorography 
with an exposure time of 72 h. 
Case reports 
Case 1 
A girl was born to a 26-year-old G~P0 mother by Caesarian 
section at 42 weeks. The mother was treated by sulphasalazine 
for Crohn's disease. Apgar scores were 2 at 1 min and 3 at 
5 rain. She required 45 min artificial ventilation. Initial met- 
abolic acidosis was treated with sodium bicarbonate. Physical 
examination demonstrated an elfin face and a blowing systolic 
ejection murmur at the lower left sternal border. She had 
short arms and legs and bilateral simian creases. On day 5, 
slow tonic clonic seizures were noted and treated by pheno- 
barbital. Throughout the first 40 days of life, she had episodic 
metabolic acidosis requiring intravenous bicarbonate adminis- 
tration. Blood lactic acid was 18.3mM. At 30 days of age 
blood bicarbonate was 11 mEq/1 despite dosage with 15 mEq 
bicarbonate/day. She became increasingly lethargic and re- 
quired ventilator support to avoid respiratory arrest. 
At  40 days of age she was transferred for evaluation. Her 
weight was 2.94 kg, and length 49 cm. She was flaccid, pale 
and very hypotonic. She was breathing spontaneously but re- 
quired a back-up ventilator rate of 15. Her corneal reflexes 
were absent on the right, and intermittently present on the 
left. She had episodic seizures. A clinical diagnosis of valvular 
aortic stenosis was made. 
On admission, serum sodium was 136 mEq/1, potassium 
2.4 mEq/1, chloride 92 mEq/1, bicarbonate 17 mEq/1, glucose 
118 mg/dl, creatinine 2.6 mg/dl, calcium 9.4 mg/dl. Blood am- 
monia was 110 gM/1, lactate 18.6 mM/1 (normal 0.5-2.2) and 
pyruvic acid 0.43 mM/1 (normal < 0.15 raM/l). Other organic 
acids were normal. 
She required increasing amounts of bicarbonate (44 mEq 
on the third day) to maintain an acceptable blood pH. Biotin 
(10 mg) per oral-gastric tube did not cause clinical improve- 
ment. A CAT scan demonstrated extensive hydrocephalus 
and loss of brain tissue. An E E G revealed slow wave activity 
with intermittent spikes. On the third hospital day she was 
given 5 mg thiamine per oral-gastric tube. During the next 
24 h, she became alkalotic with a pH of 7.62 and a bicarbonate 
level of 23 mEq/1. Bicarbonate therapy was discontinued and 
over the next 24 h she maintained a normal pH. However, she 
continued to require artificial ventilation. In view of the 
grossly abnormal CAT scan results, the patient was removed 
from the ventilator and expired on the 44th day of life. Autop- 
sy showed hydrocephalus with polymicrogyria, widespread 
past and recent necrosis of the cerebral hemisphere and brain 
stem, ectopic olivary nuclei, absent corpus callosum, and aor- 
tic valvular stenosis. 
Case 2 
A girl was hospitalised at 6 days opf age following a series of 
brief apnoeic episodes at home. Her parents are unrelated. 
Her newborn nursery course and first days at home had been 
unremarkable. Physical examination revealed a lethargic, 
hypotonic infant with periods of apnoea accompanied by 
bradycardia, lasting 20-40 s; both responded to bagging. Focal 
seizure activity (twitching of the right hand and foot) was 
noted. Initial laboratory studies included normal serum elec- 
trolytes, T4, TSH, blood count, glucose, calcium, magnesium 
and arterial blood gas determinations; serum transaminases 
and blood ammonia were at slightly elevated levels. After 
finding elevated urine and plasma alanine levels, markedly in- 
creased blood lactate (8.4 mmol/1) and pyruvate (0.66 retool/l) 
were documented. Urinary organic acid analysis showed ele- 
vations of lactate, pyruvate, and alpha-ketoglutarate. Ultra- 
sound examination of the cranium showed mild dilation of the 
lateral and third ventricles. Thiamine triphosphate synthetase 
inhibitor was absent from urine (courtesy of Dr. Jack Cooper, 
Yale University). An EEG at the age of 7 months showed a 
multifocal spike pattern. 
A brief trial with oral lipoic acid and thiamine was not fol- 
lowed by clinical or biochemical improvement. At the age of 
22 months, the patient shows marked growth retardation and 
developmental delay; her developmental age is 5-8 months 
with cognitive skills being somewhat higher than motor skills. 
She has an unusual facial appearance with prominence of the 
frontal region, bitemporal narrowing, a short, upturned nose, 
full cheeks, and a wide mouth. There is hypotonia and slight 
hyperflexia. Although she has had no further episodes of ap- 
noea, she continues to have elevated levels of blood lactate 
(5.%8.5 mmol/1) and pyruvate (0.52 mmol/1). 
Case 3 
This girl was the first-born of unrelated Caucasian parents. 
The 32-year-old, gravida 2, para 1 mother entered spontane- 
ous labour and breech delivery at term following an unevent- 
ful pregnancy. The amniotic fluid was meconium-stained. The 
2510 g infant had an Apgar score of 2 at 1 rain. Immediate 
bagging and intubation were required because of inadequate 
respiratory effort. By 2 h of age, oxygenation was adequate 
with spontaneous ventilation in room air. 
On physical examination the patient was found to be 
lethargic, hypotonic, areflexic and inactive. Respiration was 
rapid. Eye movements were minimal. Her head circumference 
was 34.2 cm (60th percentile) and crown-heel length 48 cm 
(30th percentile). The fontanelle was soft. There was no clini- 
cal or laboratory evidence of cardiopulmonary disease. There 
was micrognathia, low set ears with normal pinnae, narrow 
palpebral fissures, short neck with redundant skin, thick, 
"straight" shocky hair, genua valga, joint contractures at the 
elbows, shoulders and hips and pes cavus with hammer toes. 
The cry was weak and root, suck and gag reflexes were absent. 
Table 1. Results of enzyme analysis 
1373 1558 1585 Controls 
Patient 1 Patient 2 Patient 3 
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nmol/min per mg protein 
PDH(native) 0.015_+0.008 (9) 0.100_+0.028 (9) 0.034_+0.020 (7) 0.582_+ 
(0.332 - 
PDH (DCA activated) 0.012 _+ 0.008 (9) 0.141 + 0.044 (8) 0.029 -+ 0.010 (7) 0.749 _+ 
(0.542 - 
El Pyruvate dehydrogenase 
E2 Dihydrolipoyt transacetylase 
E3 Dihydrolipoyl dehydrogenase 
Pyruvate carboxylase 
Whole cell 1-14C-pyruvate oxidation 
nmol/min per mg 
0.322 + 0.278 (4) 0.486 + 0.188 (7) 0.492 _+ 0.173 (5) 
16.8 +3.5 (3) 25.0 (1) 17.7 (1) 
14.2 _+2.3 (4) 7.2 _+2.1 (2) 10.9 (1) 
2.1 _+0.7 (4) 3.46 (1) 0.83 (1) 





1.37 +_ 0.205 (7) 
( 0 . 7  - 3 . 5 )  
21.5 _+ 3.0 (10) 
(9.7 -36 .0 )  
6.9 _+ 1.0 (9) 
3.2 _+ 0,81 (5) 
22.2 + 4.4 (5) 
(15.7 -32 .6 )  
Values are mean + S.E. (number of determinations in parenthesis) 
Values are given for controls performed on the same day as the cell strain to be tested together with the range of those values 
DCA = dichloroacetate 
She did not  follow a light. Her  head lag was marked,  and there 
was no t runk or leg support ing response. The Moro reflex 
consisted of minimal  arm extension. Deep tendon reflexes 
were absent. There was no hepatosplenomegaly.  
There was no clinical or biochemical change following the 
oral administrat ion of thiamine (1 g/day) over 3 months.  
The initial investigation revealed a persistent metabolic 
acidosis with an elevated anion gap (pH 7.35, PCO2 29, bicar- 
bonate  16 mEq/1, sodium 138 mEq/1, potassium 4.0 mEq/1, 
chloride 106 mEq/1. The blood lactic acid concentrat ion was 
21 mmol/1 and pyruvic acid concentrat ion 0.38 mmol/1. Initial 
serum ammonia  was 176 gmol/1 (normal  less than 110), but  
this fell to 85 ~tmol/1 within 1 day. Serum amino acids, glucose, 
electrolytes, SGOT,  T4 and TSH were normal.  Chromosomes 
were normal .  There was no inhibitor  of thiamine triphosphate 
synthetase in the urine. Marked elevation of urinary lactic 
acid and alpha-ketoglutaric acid was found with a slight eleva- 
t ion of malic acid and fumaric acid. Muscle biopsy showed oc- 
casional enlarged type I fibres, but  no "ragged-red" fibres 
were present.  Electron microscopy of muscle gave normal  re- 
sults. A C T  scan on the first day showed moderate  ventricular 
enlargement  with extensive hypodensity of white matter.  
Results and diskussion 
Activities of the enzymes of pyruvate metabolism 
The activity of the pyruvate dehydrogenase complex was 
measured in cultured skin fihroblasts in the native state and 
after activation with dichloroacetate (Table 1). The activities 
of the enzyme complex in the native state were 2.6%, 5.8% 
and 17.2% of the control values, respectively while in the acti- 
vated state the values were 1.6%, 3.9% and 18.8%, respec- 
tively. There was thus, no significant activation with 
dichloroacetate. The assay system of Sheu et al. [17] in our 
hands only gives a 50% increase in activity of the pyruvate 
dehydrogenase complex after activation with dichloroacetate. 
This we believe is due to the fact that our  cells are cultured in 
ct-MEM, a pyruvate-containing culture medium. Assay of the 
three catalytic components  of the complex revealed decreased 
activity of pyruvate dehydrogenase (El),  rather than of dihy- 
drolipoyl transacetylase (E2) or of dihydrolipoyl dehydro- 
genase (E3). The higher residual activities of the pyruvate 
dehydrogenase component ,  as compared to those of the pyru- 
vate dehydrogenase complex, lead us to suggest that the 
former assay measures some other enzyme activity that decar- 
boxylates pyruvate or that the defects in E1 activity are more 
deleterious to the activity of the whole complex than to the 
PDH Complex 
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Fig. 1. Composition of the pyruvate dehydrogenase complex in bovine 
kidney (after Reed [12]). The total complex has a molecular weight of 
7.4 x 106 daltons, being made up of three catalytic components. The 
El, dehydrogenase is made up of 24 ct2132 tetramers, the o=subunit of 
which can be phosphorylated and dephosphorylated. The Ea lipoyl 
transacetylase is made up of 24 monomers of 52 kilodaltons, which ap- 
pear to be 74 kilodaltons by polyacrylamide gel electrophoresis and 
have covalently attached lipoic acid. The E 3 lipoyl dehydrogenase is 
made up of 12 dimers of 55 kilodaltons which have tight binding sites 
for flavin adenine dinucleotide (FAD) 
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isolated E1 activity, measured with artificial electron acceptors 
(Fe(CN6)3-). The activity of PDHC correlates well with the 
rate of 1-14C-pyruvate oxidation in whole cells. It might be 
postulated because of the lack of activation seen in the pyru- 
vate dehydrogenase complex of these patients that the low ac- 
tivity of the complex was due to pyruvate dehydrogenase 
phosphatase deficiency. Though we cannot eliminate this pos- 
sibility totally, it is unlikely because of the polymorphism in 
the Ela pyruvate dehydrogenase component demonstrated in 
the following section. 
Immunoprecipitation o f  the pyruvate dehydrogenase complex 
Skin fibroblasts were cultured in a medium containing 35S- 
methionine to label newly synthesised proteins and the CC14 
cell extracts incubated with anti-pyruvate dehydrogenase anti- 
serum. The immunoprecipitates formed both with this anti- 
serum and control pre-immune serum were electrophoresed 
on 12.5% polyacrylamide/sodium dodecyl sulphate gels and 
the resulting labelled protein distribution was examined by 
fluorography (Fig, i). The pattern with anti-pyruvate dehy- 
drogenase antiserum revealed the presence of dark bands cor- 
responding to proteins at 74 K, 43 K, and 36 K. These corre- 
spond to the positions of E2, ElCt and Ell3 respectively (Fig. 2), 
all members of the pyruvate dehydrogenase complex except 
that the Elct component of bovine kidney is slightly lower at 
41 K [12]. The antibody was not found to have activity to- 
wards E3 either by this technique or by Ouchterlony diffusion. 
Control serum brings down a major band at 43 K which can be 
reduced in intensity by prior pre-incubation and immuno- 
precipitation with a monoclonal antibody against actin. 
Two cell lines (1108 and 1118) with PDHC deficiency ac- 
tivities similar to 1558 (from patient 2) show the same fluoro- 
graphic pattern as the control cell line 411 (Fig. 1). However, 
the deficient cell line 1373 (from patient 1) shows a split 
double band corresponding to El(/: One of the bands is in the 
same position as actin (43 K) or the control Elct band while the 
other appears to be somewhat smaller (41 K). When a mono- 
clonal antibody against actin was used to remove actin, 1373 
Fig.2. Protein polymorphism in pyruvate dehydrogefiase-deficient 
cell lines. Proteins were immunoprecipitated from 35S-methionine 
labelled cultured skin fibroblast extracts with either control serum (C) 
or anti-pyruvate dehydrogenase antiserum (P). The immunoprecipi- 
tates were run on standard sodium dodecyl sulphate/12.5% polyacryl- 
amide electrophoretic gel and the pattern of radioactivity revealed by 
fluorography. Lanes from left to right are lane 1, protein standards 
(myos in  M r = 200000, phosphorylase b, Mr = 92500, albumin Mr = 
68000, ovalbumin Mr = 46000, carbonic anhydrase Mr = 30000); 
lane 2, control cell line 411 with control serum; lane 3 control cell line 
411 with anti-PDH anti-serum, lane 4, PDH-deficient cell line 1108 
with anti-PDH antiserum; lane 5, PDH-deficient cell line 1118 with 
anti-PDH antiserum; lane 6, PDH-deficient cell line 1373 with anti- 
PDH antiserum. Eict, EI~  indicate the positions of the ct and ~ sub~ 
units of the E1 pyruvate dehydrogenase while E2 indicates the position 
of the dihydrolipoyl transacetylase subunit from the PDH complex 
Fig.3. Immunoprecipitated 35S-labelled proteins obtained with anti- 
pyruvate dehydrogenase antiserum after treatment of the extracts 
with anti-actin antiserum. Experiments were performed as described 
for Fig. 2 except that two samples were pre-extracted with 10 gl anti- 
actin (anti-A) (Miles-monospecific) and four samples with 10 gl anti- 
actin antiserum (anti-Am) (Amcrsham monoclonal). Lane/,control 
cell line 1228 pre-immunoprecipitated by anti-A then by control 
serum; lane 2, control cell strain 1228 pre-immunoprecipitated by 
anti-A followed by anti-PDH antiserum; lane 3, control cell strain 
1228 pre-immunoprecipitated with anti-Am followed by control 
serum; lane 4 control cell strain 1228 pre-immunoprecipitated with 
anti-Am followed by anti-PDH antiserum; lane 5, PDH-deficient cell 
line 1373 pre-immunoprecipitated with anti-Am followed by control 
serum; lane 6, PDH deficient cell line 1373 pre-immunoprecipitated 
with anti-Am followed by anti-PDH antiserum 
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with moderate ventricular enlargement, while patient 2 had 
microcephaly ands ventricular dilation noted by ultrasound. 
Pyruvate dehydrogenase deficiency appears to effect the 
development of the head so that either malformation of the 
brain, microcephaly and/or facial dysmorphy may occur. Sub- 
sequently, cystic lesions may develop in the white and gray 
matter, especially in the basal ganglia. Since the brain stem is 
perhaps the most metabolically active area, areas of necrosis 
indicate that cell death is occurring. This could be due either 
to lack of intracellular ATP or to locally high concentrations 
of lactic acid secondary to the enzymatic deficiency. 
In summary, we present evidence for protein polymorph- 
ism of the E1 component in three patients with PDH-E1 defi- 
ciency. 
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Fig.4. Protein polymorphism in pyruvate dehydrogenase deficient cell 
lines. Proteins were immunoprecipitated from 35S-methionine label- 
led cultured skin fibroblast extracts with either control serum (Cs) or 
anti-pyruvate dehydrogenase antiserum (P). The immunoprecipitates 
were run on standard sodium dodecyl sulphate/12.5% polyacrylamide 
electrophoretic gel and the pattern of radioactivity revealed by fluoro- 
graphy. Lanes from left to right are: lane 1, control cell line 1228 with 
control serum; lane 2, control cell strain 1228 with anti-PDH anti- 
serum; lane 3, PDH-deficient cell strain 1558 with control serum; 
lane 4, 1558 with anti-PDH antiserum; lane 5, 6, 7, 8, PDH-deficient 
cell strains 1360, 1552, 1573 and 1585 with anti-pyruvate dehy- 
drogenase antiserum. Elct and Ed3 indicate the position of a and 
subunits of the E1 pyruvate dehydrogenase component 
showed only a predominant 41 K band (Fig. 3). When mono- 
specific antibody to actin was used it did not appear to remove 
the contaminating actin band as effectively with preservation 
of the PDH-specific antigens. The two other PDHC-deficient 
cell lines 1585 (patient 3) and 1558 (patient 2) showed the 
double band demonstrated in 1373, which was not seen in ten 
other PDHC-deficient cell lines tested nor in any control cell 
line tested (Fig. 4). 
Despite the fact that these three children had the same 
basic enzyme defect, they showed some differences. Patient 2 
had facial dysmorphism with microcephaly, patient 3 had less 
pronounced features of dysmorphism and patient 1 had a nor- 
mal appearance. Two of the children had increased a-keto- 
glutarate excretion in the urine. All three had lacticacidaemia, 
difficult to control and (patient 1) died in the neonatal period. 
In this child, the brain was already morphologically affected at 
birth, showing agenesis of the corpus callosum and ectopic 
olivary nuclei. The brain stem showed cystic lesions at autop- 
sy. A C T  scan revealed hypodense white matter in patient 3 
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SVYDROM~S are the signpost and compass and map which direct us through the 
crowded twisting streets, the oceans, and the jungles of medical experience. 
They are not points of arrival, nor things. They are not immutable, and are 
always to be reviewed critically. A full understanding of the logical system 
implied by the syndrome should enable us to guide our patient with confi- 
dence and wisdom; should suggest and direct our researches; and should 
refresh our sense of gratidue to our medical forefathers. 
William Gooddy, Lancet 1" 1, 1961 
